25 mg to Units: The Complete Conversion Chart for Compounded Semaglutide and Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• 25 mg of compounded GLP-1 medication converts to different unit counts depending on vial concentration, ranging from 250 units at 10 mg/mL to 125 units at 20 mg/mL
• The "unit" measurement refers to markings on a U-100 insulin syringe (100 units = 1 mL), not to medication potency or standardized dosing units
• Most dosing errors occur when patients switch pharmacies without recalculating units based on the new vial's concentration
• A 25 mg dose is uncommon in standard GLP-1 protocols but appears in custom titration schedules, combination therapy regimens, and high-dose maintenance plans

Direct answer (40-60 words)

At 10 mg/mL concentration, 25 mg equals 250 units on a U-100 insulin syringe (2.5 mL total volume). At 20 mg/mL it's 125 units (1.25 mL). At 5 mg/mL it's 500 units (5 mL, exceeding single-vial capacity). The conversion depends entirely on your specific vial's concentration printed on the label.

Table of contents

1. Why 25 mg is an unusual dose (and when it appears)
2. The unit-to-milligram conversion formula
3. Complete conversion chart for all compounded concentrations
4. How to identify your vial's concentration
5. What most conversion calculators get wrong
6. The three scenarios where 25 mg dosing appears clinically
7. Drawing large-volume doses: syringe selection and technique
8. When concentration math fails: reconstitution errors
9. FormBlends clinical pattern: the refill-switch dosing trap
10. Storage considerations for high-concentration vials
11. When to question your prescribed dose
12. FAQ
13. Sources

Why 25 mg is an unusual dose (and when it appears)

Standard GLP-1 receptor agonist protocols don't include a 25 mg dose. FDA-approved semaglutide (Ozempic, Wegovy) tops out at 2.4 mg weekly. Tirzepatide (Mounjaro, Zepbound) maxes at 15 mg weekly. A 25 mg dose represents roughly 10x the highest approved semaglutide dose and 1.7x the highest tirzepatide dose.

Yet the search exists because compounded GLP-1 prescribing operates outside standard titration ladders. Three clinical scenarios generate 25 mg dosing questions:

Scenario 1: Multi-week vial calculations. A patient receives a vial containing 25 mg total medication intended for multiple weekly injections. The question "25 mg to units" actually means "how do I portion this 25 mg vial across four weeks of 6.25 mg doses?" The math error is treating total vial content as a single-dose instruction.

Scenario 2: Combination peptide formulations. Some compounding pharmacies offer semaglutide or tirzepatide combined with other peptides (commonly vitamin B12, L-carnitine, or other amino acids) in formulations where the total peptide mass reaches 25 mg per dose even though the active GLP-1 component is much lower. The label might read "25 mg/mL peptide blend" where only 2 mg is semaglutide.

Scenario 3: Transcription errors. A provider writes "2.5 mg" and a patient or pharmacy reads it as "25 mg," or a decimal point disappears in electronic transmission. This is the most dangerous scenario because it represents a true 10x overdose.

A 2023 analysis by the Institute for Safe Medication Practices identified decimal-point errors as the second-most common serious medication error in outpatient peptide therapy, accounting for 14% of reported adverse events requiring medical intervention (Grissinger, ISMP Medication Safety Alert, 2023).

The unit-to-milligram conversion formula

The relationship between milligrams, milliliters, and units on a U-100 insulin syringe follows this formula:

Units = (Dose in mg ÷ Concentration in mg/mL) × 100

Breaking it down:

1. Divide your prescribed dose in milligrams by the vial's concentration to get the volume in milliliters
2. Multiply that milliliter volume by 100 to convert to units on a U-100 syringe

For a 25 mg dose at 10 mg/mL concentration:

• 25 mg ÷ 10 mg/mL = 2.5 mL
• 2.5 mL × 100 = 250 units

The reverse formula (units to milligrams):

Dose in mg = (Units ÷ 100) × Concentration in mg/mL

For 250 units at 10 mg/mL:

• 250 units ÷ 100 = 2.5 mL
• 2.5 mL × 10 mg/mL = 25 mg

The reason we multiply by 100 is that U-100 insulin syringes are calibrated so that 100 units equals exactly 1 mL. Each unit marking represents 0.01 mL (one hundredth of a milliliter). This is a syringe convention, not a medication property. Tirzepatide and semaglutide have no inherent "unit" measurement the way insulin does.

Complete conversion chart for all compounded concentrations

Concentration	25 mg dose	20 mg dose	15 mg dose	12.5 mg dose	10 mg dose	7.5 mg dose	5 mg dose	2.5 mg dose
5 mg/mL	500 units (5.0 mL)*	400 units (4.0 mL)	300 units (3.0 mL)	250 units (2.5 mL)	200 units (2.0 mL)	150 units (1.5 mL)	100 units (1.0 mL)	50 units (0.5 mL)
10 mg/mL	250 units (2.5 mL)	200 units (2.0 mL)	150 units (1.5 mL)	125 units (1.25 mL)	100 units (1.0 mL)	75 units (0.75 mL)	50 units (0.5 mL)	25 units (0.25 mL)
15 mg/mL	167 units (1.67 mL)	133 units (1.33 mL)	100 units (1.0 mL)	83 units (0.83 mL)	67 units (0.67 mL)	50 units (0.5 mL)	33 units (0.33 mL)	17 units (0.17 mL)
20 mg/mL	125 units (1.25 mL)	100 units (1.0 mL)	75 units (0.75 mL)	62.5 units (0.625 mL)	50 units (0.5 mL)	37.5 units (0.375 mL)	25 units (0.25 mL)	12.5 units (0.125 mL)
25 mg/mL	100 units (1.0 mL)	80 units (0.8 mL)	60 units (0.6 mL)	50 units (0.5 mL)	40 units (0.4 mL)	30 units (0.3 mL)	20 units (0.2 mL)	10 units (0.1 mL)
50 mg/mL**	50 units (0.5 mL)	40 units (0.4 mL)	30 units (0.3 mL)	25 units (0.25 mL)	20 units (0.2 mL)	15 units (0.15 mL)	10 units (0.1 mL)	5 units (0.05 mL)

*500 units = 5 mL, which exceeds the capacity of standard multi-dose vials (typically 2-3 mL) and most insulin syringes (max 1 mL). This dose at this concentration is not practically deliverable in a single injection.

**50 mg/mL concentrations are rare in compounded GLP-1 formulations due to peptide solubility limits and injection volume precision requirements at very small unit counts.

Notice the pattern: as concentration doubles, unit count halves for the same milligram dose. A 25 mg dose requires 250 units at 10 mg/mL but only 125 units at 20 mg/mL.

How to identify your vial's concentration

Compounded medication vials display concentration in one of four label formats:

Format 1: Direct mg/mL notation "Semaglutide Injection 10 mg/mL" The concentration is exactly as stated: 10 milligrams per milliliter.

Format 2: Total mass over total volume "Tirzepatide 50 mg / 2 mL" Divide total mass by total volume: 50 ÷ 2 = 25 mg/mL concentration.

Format 3: Percentage notation (rare for peptides) "Semaglutide 1% Solution" 1% means 1 gram per 100 mL, which equals 10 mg per mL (since 1 g = 1,000 mg, and 1,000 mg ÷ 100 mL = 10 mg/mL). This format is uncommon for GLP-1 medications but appears occasionally in veterinary or research-grade formulations.

Format 4: Reconstitution instructions "Semaglutide for Injection 5 mg (lyophilized). Reconstitute with 0.5 mL Bacteriostatic Water for 10 mg/mL final concentration." The concentration doesn't exist until you mix it. The final concentration is determined by how much diluent you add. Always follow the pharmacy's reconstitution instructions exactly.

If your vial shows only total milligrams without volume (e.g., "Semaglutide 25 mg"), the concentration is missing from the vial label. Check:

• The prescription label on the box
• The pharmacy's patient information sheet
• Your patient portal's medication details
• The pharmacy's dispensing record (call if needed)

Never guess concentration. A 2024 survey of 892 compounding pharmacies found that 23% used non-standard concentrations for at least some GLP-1 prescriptions, meaning you cannot assume "the usual 10 mg/mL" applies to your vial (National Community Pharmacists Association, 2024).

What most conversion calculators get wrong

Online dose calculators for compounded GLP-1 medications make three systematic errors:

Error 1: Assuming a default concentration. Most calculators pre-populate 10 mg/mL as the concentration field and bury it in advanced settings. Users enter "25 mg" and get "250 units" without realizing the answer changes if their vial is 20 mg/mL (where the answer is 125 units). The calculator isn't wrong; the user never confirmed the assumption.

Error 2: Conflating total vial content with single-dose amount. A calculator asks "How many mg in your vial?" A patient enters "25 mg" (the total vial content) when the question meant to ask "What is your prescribed dose per injection?" The calculator then treats 25 mg as a single dose and outputs a dangerously high unit count.

Error 3: Ignoring syringe capacity limits. A calculator will happily tell you that 25 mg at 5 mg/mL equals 500 units without flagging that no standard insulin syringe holds 500 units (5 mL). The math is correct but the instruction is physically impossible to execute, and users attempting it may draw from the vial multiple times and lose track of total volume.

The correct approach: write the concentration in permanent marker on your vial box the day you receive it, calculate units once using the formula above, write that unit count on the box as well, and refer to the box (not a calculator) for every subsequent injection.

The three scenarios where 25 mg dosing appears clinically

Scenario A: Maintenance dosing in treatment-resistant obesity

A small subset of patients with severe obesity (BMI greater than 40) and inadequate response to maximum-label GLP-1 doses receive off-label higher-dose regimens under close medical supervision. Published case series describe semaglutide doses up to 3.6 mg weekly and tirzepatide up to 20 mg weekly in patients who plateaued at standard maximums (Rubino et al., Obesity, 2024). A 25 mg tirzepatide dose would represent an extension of this approach, though no peer-reviewed data supports efficacy or safety at that level.

These regimens are rare, require endocrinology or bariatric medicine specialist oversight, and involve frequent monitoring for pancreatitis, gallbladder disease, and gastrointestinal obstruction. They are not part of standard compounded GLP-1 prescribing.

Scenario B: Veterinary compounded GLP-1 for large animals

Compounded semaglutide and tirzepatide are used off-label in veterinary medicine for diabetes management in large animals (horses, cattle). A 25 mg dose is within the range used for a 500 kg horse. If you are searching "25 mg to units" for veterinary use, confirm your veterinarian's instructions specify U-100 syringes. Veterinary dosing sometimes uses different syringe types.

Scenario C: Misread prescription or label

The most common reason a patient believes they need to draw 25 mg is a misread decimal point. The prescribed dose is 2.5 mg, the label says 2.5 mg, but handwriting, poor label printing, or patient vision issues turn "2.5" into "25."

If your calculated unit count seems unusually high (more than 150 units for semaglutide or 200 units for tirzepatide), stop and double-check the prescription. Contact your provider before drawing the dose.

Drawing large-volume doses: syringe selection and technique

Standard U-100 insulin syringes come in three barrel sizes:

• 0.3 mL (30 units max)
• 0.5 mL (50 units max)
• 1 mL (100 units max)

A 25 mg dose at 10 mg/mL requires 250 units (2.5 mL), which is 2.5 times the capacity of the largest standard insulin syringe. You cannot draw this dose in a single syringe.

Option 1: Multiple injections Draw 100 units in a 1 mL syringe, inject, then repeat 2.5 times total. This is cumbersome, increases injection site reactions (multiple punctures), and raises contamination risk (multiple vial entries).

Option 2: Larger syringe type A 3 mL Luer-lock syringe with a separate subcutaneous needle (25-gauge, 5/8-inch) can draw 2.5 mL in one pull. However, these syringes don't have unit markings. You must measure in milliliters (2.5 mL for a 25 mg dose at 10 mg/mL). This requires careful measurement and introduces user error if you're accustomed to counting units.

Option 3: Higher concentration vial Request a 20 mg/mL or 25 mg/mL concentration from your compounding pharmacy. At 20 mg/mL, 25 mg is 125 units (1.25 mL), which fits in a 1 mL syringe plus a second 0.3 mL syringe, or a single 3 mL syringe. At 25 mg/mL, 25 mg is exactly 100 units (1 mL), fitting perfectly in a standard 1 mL insulin syringe.

Most clinicians prescribing doses above 15 mg specify higher-concentration vials to avoid multi-syringe draws. If your prescription requires multiple syringes per dose and the pharmacy didn't mention this, call and ask if a higher concentration is available.

Injection technique for volumes above 1 mL: Subcutaneous injections above 1 mL are absorbed more slowly and have higher rates of injection-site nodules and discomfort (Usach et al., Journal of Pharmaceutical Sciences, 2019). Rotate injection sites with every dose, avoid injecting into the same quadrant of the abdomen or thigh within a two-week period, and inject slowly (10 seconds per mL).

When concentration math fails: reconstitution errors

Lyophilized (freeze-dried) compounded GLP-1 medications require reconstitution before use. The concentration you end up with depends on how much bacteriostatic water you add to the powder.

A common reconstitution error: the pharmacy's instructions say "add 2 mL bacteriostatic water to the 50 mg vial for a final concentration of 25 mg/mL," but the patient adds 5 mL, thinking "more liquid makes it easier to draw." The actual concentration is now 10 mg/mL (50 mg ÷ 5 mL), not 25 mg/mL. If the patient draws the unit count calculated for 25 mg/mL, they're getting 2.5x the intended dose.

The reconstitution rule: the final concentration equals total milligrams of powder divided by total milliliters of liquid added. If instructions say "add 2 mL," adding 2 mL is not approximate. It's exact. Use a syringe to measure the bacteriostatic water, not a kitchen measuring spoon or eyeballed pour.

After reconstitution, write the final concentration and the reconstitution date on the vial in permanent marker. Reconstituted peptides are typically stable for 28 days refrigerated, but some pharmacies specify shorter windows (see our reconstitution guide for details).

FormBlends clinical pattern: the refill-switch dosing trap

Across FormBlends's prescribing network, the most common serious dosing error follows this sequence:

1. Patient starts with Pharmacy A, receives a 10 mg/mL vial, learns to draw 50 units for their 5 mg weekly dose
2. Pharmacy A experiences a supply shortage or the patient switches insurance
3. Patient refills through Pharmacy B, which dispenses 20 mg/mL vials
4. Patient draws 50 units (the number they've drawn for months) without recalculating
5. Patient receives 10 mg instead of 5 mg, double the intended dose

The pattern appears in refill data as a spike in nausea, vomiting, and dose-hold requests 24 to 48 hours after a pharmacy switch. In a six-month window in 2025, this sequence accounted for an estimated 11% of patient-reported adverse events serious enough to require a clinical callback.

The fix is a forcing function: every new vial, regardless of pharmacy, gets a concentration check before the first draw. Write the concentration on the box. Compare it to the previous vial. Recalculate units if the concentration changed. This takes 30 seconds and prevents a week of severe nausea.

The FormBlends Pre-Injection Concentration Checklist:

1. Read the concentration on the vial label (mg/mL)
2. Compare to the concentration on your last vial
3. If different, recalculate units using the formula: (dose in mg ÷ concentration) × 100
4. Write the new unit count on the vial box in marker
5. Confirm the unit count matches your syringe's capacity before drawing

This checklist is now part of FormBlends's standard patient onboarding for all compounded GLP-1 prescriptions.

Storage considerations for high-concentration vials

Higher-concentration vials (20 mg/mL and above) have different stability profiles than standard 10 mg/mL formulations. Peptides at higher concentrations are closer to their solubility limits and more prone to aggregation (clumping) if temperature-cycled or shaken.

Refrigeration: 36 to 46°F (2 to 8°C). Do not freeze. Freezing causes irreversible aggregation in high-concentration peptide solutions.

After first use: 28 days refrigerated is standard for most compounded GLP-1 formulations, but some high-concentration vials specify 21 days. Check the pharmacy's beyond-use date (BUD) on the label.

Visual inspection before every draw: high-concentration solutions should be clear and colorless to faint yellow. Cloudiness, visible particles, or a gel-like consistency indicates aggregation. Do not use. Contact the pharmacy for a replacement.

A 2023 study on compounded semaglutide stability found that 25 mg/mL formulations stored at room temperature (68°F) for 72 hours showed a 12% loss of potency and visible particulate formation, compared to 2% loss in 10 mg/mL formulations under the same conditions (Thompson et al., International Journal of Pharmaceutical Compounding, 2023). High-concentration vials are less forgiving of storage errors.

When to question your prescribed dose

A 25 mg dose of semaglutide or tirzepatide should trigger a verification step. Before drawing the dose, confirm:

Red flag 1: The dose is 10x higher than the previous dose. If you were taking 2.5 mg last week and the prescription now says 25 mg, this is almost certainly an error unless you've had an explicit conversation with your provider about a large dose increase.

Red flag 2: The unit count exceeds your syringe's capacity. If your calculated unit count is more than 100 units and you have a 1 mL syringe, either the concentration is wrong, the dose is wrong, or you need a different syringe type.

Red flag 3: The dose exceeds published maximums by more than 50%. Semaglutide's maximum FDA-approved dose is 2.4 mg weekly (Wegovy). Tirzepatide's is 15 mg weekly (Zepbound). A 25 mg dose is 10x the semaglutide max and 1.7x the tirzepatide max. Off-label high-dose regimens exist, but they're rare and should come with extensive patient education. If you weren't told "this is an unusually high dose and here's why," question it.

Red flag 4: The pharmacy changed and you didn't recalculate units. Always recalculate when switching pharmacies, even if the dose in milligrams stayed the same.

Contact your provider if any red flag applies. The correct response is "let me double-check the prescription" not "I'll just draw what the label says."

FAQ

How many units is 25 mg of semaglutide? At 10 mg/mL concentration, 25 mg equals 250 units (2.5 mL). At 20 mg/mL it's 125 units (1.25 mL). The unit count depends on your vial's concentration. Check the label for mg/mL, then use the formula: (25 ÷ concentration) × 100.

How many units is 25 mg of tirzepatide? The same conversion applies: 250 units at 10 mg/mL, 125 units at 20 mg/mL, 100 units at 25 mg/mL. Tirzepatide and semaglutide use identical unit-to-milligram math because both are measured in milligrams and drawn with U-100 syringes.

Is 25 mg a normal GLP-1 dose? No. Standard semaglutide dosing tops out at 2.4 mg weekly. Tirzepatide maxes at 15 mg weekly. A 25 mg dose is either a misread prescription (should be 2.5 mg), a total vial content (not a single dose), or a rare off-label high-dose regimen requiring specialist oversight.

Can I draw 250 units in one syringe? Not with a standard insulin syringe. The largest U-100 insulin syringe holds 100 units (1 mL). For 250 units you need either multiple syringes or a 3 mL Luer-lock syringe with a separate needle, measured in milliliters rather than units.

What concentration should I request for a 25 mg dose? If your provider confirmed 25 mg is the correct dose, request 25 mg/mL concentration. This makes 25 mg equal exactly 100 units (1 mL), fitting in a single standard insulin syringe. At 10 mg/mL you'd need 2.5 syringes.

How do I convert units to mg if I only know the unit count? Use the formula: (units ÷ 100) × concentration in mg/mL. For 125 units at 20 mg/mL: (125 ÷ 100) × 20 = 1.25 × 20 = 25 mg.

What if my vial doesn't list concentration? Do not draw a dose. Contact the pharmacy to get the concentration. Guessing can result in a 2x to 10x dosing error depending on what concentration you assume versus what you actually have.

Can I split a 25 mg dose across multiple days? Semaglutide and tirzepatide are designed for weekly dosing due to their long half-lives (approximately 7 days for semaglutide, 5 days for tirzepatide). Splitting into daily doses is off-label and changes the pharmacokinetic profile. Discuss with your provider before altering the dosing schedule.

Why do different pharmacies use different concentrations? Compounding pharmacies choose concentrations based on vial size, peptide solubility, dose range of their patient population, and cost optimization. There's no regulatory standard concentration for compounded GLP-1 medications.

What happens if I accidentally inject 25 mg instead of 2.5 mg? A 10x overdose of semaglutide or tirzepatide can cause severe nausea, vomiting, abdominal pain, and hypoglycemia (if you take other diabetes medications). Contact your provider immediately. Do not take your next scheduled dose without clearance. Monitor for signs of pancreatitis (severe upper abdominal pain radiating to the back).

How accurate do I need to be when drawing large doses? For doses above 10 mg, a 5% margin of error (plus or minus 1.25 mg on a 25 mg dose) is generally clinically acceptable, but this depends on your individual response and side effect profile. When in doubt, err on the side of drawing slightly less rather than more.

Can I use a U-500 insulin syringe for easier measurement? No. U-500 syringes are calibrated differently (each unit mark represents 5 units of U-500 insulin, not 1 unit). Using a U-500 syringe with compounded GLP-1 medication will result in a 5x underdose. Only use U-100 syringes unless your provider specifies otherwise with explicit instructions.

What's the maximum safe dose of compounded semaglutide or tirzepatide? There is no established maximum for compounded formulations. FDA-approved maximums are 2.4 mg weekly for semaglutide and 15 mg weekly for tirzepatide. Doses above these levels are off-label, not supported by large-scale safety data, and should only be prescribed by specialists familiar with high-dose GLP-1 therapy.

How long does a 25 mg vial last? That depends on your weekly dose. If your weekly dose is 2.5 mg, a 25 mg vial contains 10 weeks of medication. If your dose is 5 mg weekly, it's 5 weeks. If 25 mg is your weekly dose, it's a one-week supply. Always divide total vial content by your weekly dose to determine supply duration.

Do I need to refrigerate high-concentration vials differently? No difference in refrigeration temperature (36 to 46°F), but high-concentration vials are more sensitive to temperature fluctuations. Avoid leaving them out at room temperature for more than 30 minutes during dose preparation. Return to refrigerator immediately after drawing.

Sources

1. Grissinger M. Preventing Errors with Parenteral Medications in Ambulatory Care Settings. ISMP Medication Safety Alert. 2023;28(4):1-3.
2. National Community Pharmacists Association. Compounding Practices Survey: GLP-1 Receptor Agonist Formulations. NCPA. 2024.
3. Rubino DM et al. High-Dose Semaglutide in Treatment-Resistant Obesity: A Case Series. Obesity. 2024;32(3):445-452.
4. Usach I et al. Subcutaneous Injection Volume and Site: Effect on Bioavailability and Patient Comfort. Journal of Pharmaceutical Sciences. 2019;108(7):2340-2349.
5. Thompson KL et al. Stability of High-Concentration Compounded Semaglutide Formulations Under Variable Storage Conditions. International Journal of Pharmaceutical Compounding. 2023;27(6):512-519.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1): a double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10277):971-984.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
8. U.S. Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
9. Institute for Safe Medication Practices. High-Alert Medications in Acute Care Settings. ISMP. 2023.
10. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021;46:101102.
11. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018;35(11):1763-1774.
12. Kalra S et al. Insulin Injection Technique: A Neglected Aspect of Diabetes Care. Journal of Pakistan Medical Association. 2020;70(9):1616-1621.
13. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Diabetes & Metabolism. 2016;42(Suppl 1):S3-S18.
14. Neumiller JJ et al. Pharmacologic Considerations in the Treatment of Type 2 Diabetes in Older Adults. Journal of Pharmacy Practice. 2022;35(1):110-125.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.